Scynexis
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Scynexis announced on September 25, 2023, that it would initiate a recall of ibrexafungerp tablets from the market and temporarily halt clinical studies of ibrexafungerp. This decision stemmed from a recent evaluation revealing that equipment used in the production of ibrexafungerp was also employed in the manufacturing of a non-antibacterial beta-lactam drug substance. This shared equipment posed the potential risk of acting as sensitizing agents, potentially causing hypersensitivity or allergic reactions in certain individuals.
Following this announcement, Scynexis’s stock price experienced a significant decline of $1.13, representing a 34.1% decrease, resulting in a closing price of $2.18 per share on September 25, 2023, which resulted in harm to investors.
